<?xml version="1.0" encoding="UTF-8"?>
<p>There is no clear indication and evidence of benefit by using CP for prophylaxis for those who have been exposed to SARS‐CoV‐2, this issue is still controversial and FDA does not allow the use of CP for prophylaxis outside of approved clinical trials.
 <xref rid="jca21806-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="jca21806-bib-0016" ref-type="ref">
  <sup>16</sup>
 </xref> However, historically, it has been stated that passive antibody therapy is most effective when administered prophylactically or used early after the onset of symptoms.
 <xref rid="jca21806-bib-0030" ref-type="ref">
  <sup>30</sup>
 </xref>, 
 <xref rid="jca21806-bib-0031" ref-type="ref">
  <sup>31</sup>
 </xref> The new, phase 2‐3 trial is recruiting patients and still evaluating the use of post‐exposure prophylactic plasma in COVID‐19 patients who have had close contact exposure, but have not yet presented symptoms.
 <xref rid="jca21806-bib-0032" ref-type="ref">
  <sup>32</sup>
 </xref>
</p>
